REDVET - Revista electrónica de Veterinaria - ISSN 1695-7504
Vol 24, No. 2 (2023)
http://www.veterinaria.org
Article Received: 04 April 2023; Revised: 28 May 2023; Accepted: 21 June 2023

Assessing the Efficacy of New Chemical Compounds in Treating Alzheimer's disease in Animal Models

Krishana Kumar Sharma[1], Asha.K[2], Dr. Hemlata Sharma[3]

[1]Professor, College of Pharmacy, Teerthanker Mahaveer University, Moradabad, Uttar Pradesh, India, Email Id: drkk108@gmail.com

[2]Assistant Professor, Department of Life Science, School of Sciences, JAIN (Deemed-to-be University), Karnataka, India, Email id: k.asha@jainuniversity.ac.in

[3]Assistant Professor, Department of Ayurveda, Sanskriti University, Mathura, Uttar Pradesh, India, Email id: hemlata.ayurveda@sanskriti.edu.in

Abstract

Alzheimer's disease (AD) is a severe condition that causes damage to the nervous system. The present approach of treating AD is inefficient at bringing the condition under long-term management and is also linked to a number of adverse consequences, including dyskinesia. The creation of non-dopaminergic remedies for AD aims to produce therapeutics that may alleviate motor deficiencies without running the risk of the chronic side effects connected with conventional dopaminergic drugs. One such target is the mGluR4 metabotropic glutamate receptor, which is now the focus of research. The possibility exists to propose mGluR4 activation as a new and promising therapy for Parkinson's disease. Additionally, applying a positive allosteric modulator to the orthosteric glutamate site rather than using direct acting agonists is seen to be a legitimate and effective therapy option for AD. The development of preclinical drugs has also benefited from the use of animal models. To evaluate a candidate compound's effectiveness, safety, and pharmacokinetics, animal testing can be done. Clinical trials on humans are being conducted as a result of promising results from therapeutic approaches that target A, tau, neuroinflammation, or other pathogenic characteristics. Additionally, non-pharmacological therapies that have shown cognitive advantages in AD models, including as exercise and environmental enrichment, have been examined in animal models.

Keywords: AD patients, toxicity, standard dopaminergic drugs, Transmission Assessment Survey (TAS-4)

Introduction

AD is characterized by early memory loss and progressive cognitive deterioration in the hippocampus, cortical, and subcortical regions, including the amygdala and nucleus basalis of Meynert. Amyloid plaques, neurofibrillary lesions, and significant loss of neuronal cells and synapses are all visible on neuropathology slides. The neurofibrillary tangles are hyperphosphorylated tau aggregates, while the plaques are mostly composed of peptide A from APP in (Figure1). Familial AD (FAD) is caused by autosomal dominant mutations in three genes, APP, presenilin-1(PSEN1), and PSEN2, in less than 1% of cases. The proteolytic enzymes -secretase and -secretase convert presenilins into A. According to genome-wide studies, PSEN1 and PSEN2 pathogenic mutations are the source of FAD, while apolipoprotein E (APOE) and other susceptible genes are the cause of sporadic AD (SAD).

REDVET - Revista electrónica de Veterinaria - ISSN 1695-7504
Vol 24, No. 2 (2023)
http://www.veterinaria.org
Article Received: 04 April 2023; Revised: 28 May 2023; Accepted: 21 June 2023



Figure (1): The main characteristics of neuropathology AD

AD is a neurological illness that affects millions. It entails behavioural problems, cognitive decline, and memory loss. Despite much research, symptomatic relief is the only treatment for AD. For this horrible condition to be postponed or stopped, new therapeutic approaches are required (1). The research (2) Examined novel chemical compounds in animal models is a promising strategy in the hunt for possible Alzheimer's therapy. In order to explore the pathological processes underlying AD and to assess the effectiveness and safety of possible treatment medicines before moving them forward to human clinical trials, animal models play a significant role in preclinical research.

The study (3) proposed, possible chemical agents for treating AD are tested using animal models. Drugs that target amyloid-beta plaques, neurofibrillary tangles, synaptic dysfunction, and neuro inflammation have shown promising early in vitro findings. Animal models for Alzheimer's will be used to evaluate these chemicals. These models often use genetically altered mice with amyloid-beta plaques, neuronal loss, neurofibrillary tangles, and cognitive deficits. Animal models can assess changes in cognition, behaviour, biochemistry, and histology caused by sickness (4). Multiple chemical compound treatment protocols will be part of a full experimental design. Animals may be exposed to chemicals orally, intravenously, or in various ways, depending on the material. The morris water maze, new item recognition, and fear conditioning paradigms will all be tested cognitively. Analyses of the chemicals' effects on amyloid-beta levels, tau phosphorylation, synaptic markers, and neuroinflammatory markers will also be conducted by biochemical and histological methods (5). The article (6) proposed preclinical information from known AD targets may help clinical researchers choose, improve, and translate New Chemical Entity (NCE) and biologics. There are still significant limitations in the understanding, approval, and inquiry of existing animal models of AD, despite the fact that many of these failures are due to flawed

REDVET - Revista electrónica de Veterinaria - ISSN 1695-7504
Vol 24, No. 2 (2023)
http://www.veterinaria.org
Article Received: 04 April 2023; Revised: 28 May 2023; Accepted: 21 June 2023

hypotheses or insufficient assessment of accessibility, toxic effects, and preclinical pharmacodynamic and pharmacokinetic (PD/PK) characteristics of the primary NCEs. The research (7) indicated unsurprising given the weak external validity of the animal models. Even though the animal models all exhibit the same signs of AD, none of them fully captures the condition. Scientists failed to address the characteristics of the species that influence the outcomes, did not discuss why one model was favored over another, and did not account for how the sickness occurrences were formed. The article (8) provided a thorough review of recent developments Design concepts, optical features, A-binding capacities, and possible applications in AD mice models are highlighted in creating molecular NIR fluorescent probes for in vivo sensing and imaging. The study (9) proposed in order to investigate its potential as a multitarget drug; a novel feruloyl-donepezil hybrid molecule was developed. It's interesting to note that PQM130 has anti-inflammatory and neuroprotective properties in human brain cells and in vivo models. Memory loss, oxidative stress, neurodegeneration, and neuroinflammation were all brought on by intracerebroventricular injections in mice.

The study (10) provided an overview of the connections connecting cell biology, neuropathology, clinical phenotype, and biomarker development in human AD. The most efficient way to separate the many pathways behind AD is to use genetically modified animals in conjunction with new stem cell systems. These animals have offered important insights into the cell biology of AD. The article (11) proposed the most neuroprotective and anti-inflammatory compounds were Epigallocatechin-3-Gallate (EGCG), Docosahexaenoic acid (DHA), and Alpha-Lipoic Acid (ALA). Our findings also demonstrate the potential for adverse interactions between nutraceutical items, underlining the need for animal models and/or human clinical studies before producers of combination products may assert any additive or synergistic benefits in vivo. The article (12) looked into if giving galantamine before the A buildup, which is a sign of AD, may prevent the irreversible negative cascade from starting and so postpone the development of the disease. Additionally, we looked examined whether it was feasible to monitor the brain redox state in AD model mice using the EPR imaging approach to assess the pathogenic condition and the therapy impact. The article (13) provided an overview of the use of chinmedomics in identifying potential biomarkers for a condition and demonstrating the effectiveness of the associated treatment. We also draw attention to the identification of Q indicators and lead compounds from Traditional Chinese Medicine (TCM). "Evaluation of New Chemical Entities in Animal Models of AD": This review article examines the evaluation of novel chemical compounds in these animal models and offers an outline of the many animal models that have been employed in AD research. To assess the possible therapeutic effects of substances, it includes themes including cognitive testing, behavioural experiments, and biochemical investigations (14).

Evaluation of Potential Therapeutics for AD: This study proposed the preclinical assessment of prospective treatment approaches for AD is included. It gives insights into the difficulties and factors involved in evaluating the effectiveness of novel chemical compounds and cover a variety of methodologies, including the use of animal models (15).

REDVET - Revista electrónica de Veterinaria - ISSN 1695-7504
Vol 24, No. 2 (2023)
http://www.veterinaria.org
Article Received: 04 April 2023; Revised: 28 May 2023; Accepted: 21 June 2023

Methodology

Hypothesis

H0. The in-vitro efficacy of mGluR 4 PAMs in tests for calcium mobilisation using mGluR4/Gqi5/Chinese hamster ovary cells has not changed much. The acronym mGluR4 refers to mGluR4/Chinese hamster ovarian cells.
H1. The in-vitro efficacy of mGluR 4 PAMs has significantly changed in tests for calcium mobilisation using mGluR4/Gqi5/Chinese Hamster Ovary Cells. The acronym mGluR4 refers to mGluR4/Chinese hamster ovarian cells.
H2. The degree of selectivity shown by TAS-4 in comparison to other mGluR receptors has not changed much.
H3. TAS-4's level of selectivity in relation to other mGluR receptors has changed significantly.
H4. The acute oral toxicity of TAS-4 to female Wistar rats has not changed much, and the compound's manufacturing should be scaled up.
H5. The acute oral toxicity of TAS-4 in female Wistar rats has changed significantly, and the manufacture of the chemical has been scaled up.

Based on the Functional Efficacy of Test Compounds, Calcium Mobilisation Test Results

A 96-well black-walled, clear-bottomed tissue culture plate containing Dulbecco's Modified Eagle's Medium (DMEM) with 10% Fetal Bovine Serum (FBS), penicillin and streptomycin at a concentration of 100 units/ml and sodium pyruvate at a concentration of 1 millimolar (Mm) was used as the plating medium. Each well contained 50,000 human Metabotropic glutamate receptors (mGluR4)/Gqi5/Chinese hamster ovary cells.

The cells were cultured for the whole night at a temperature of 37 degrees Celsius and a 5% carbon dioxide concentration. The medium was removed the next day and 20 l of 1 M Fluo-4 AM was replaced. It was prepared as a stock solution of 1 mM in DMSO before usage. The solution was subsequently diluted using an experiment buffer, 1% BSA, 30 min at 37 degrees Fahrenheit with 2.5 mM, etc., by Sigma. After being mixed in a 1:1 ratio with 10 percent (w/v) of the pluronic acid F-127. 100 l of the assay buffer were then added after the dye was removed. Concentration-response curves (CRCs, 9 points, ranging from roughly 10 M-1 nM (nanomolar) at 0.5% final DMSO concentration) were used to assess the potency of each test compound using a calcium assay in which cells express the recombinant G enzyme Gqi5 to link mGlu4 to ca mobilisation. These CRCs had a final DMSO concentration of 0.5% and a range of around 1 nM. Utilising the Flex Station III (Molecular Devices) and a fluorescence baseline of 15 seconds (excitation: 488 nm; emission: 535 210 nm), the Ca2+ flow was monitored. A 5X compound stock was prepared such that 20 l of the cells received compounds. Using a fluorescent baseline, Ca2+ flow is evaluated.

The machine automatically injected the glutamate after 15 seconds. The increase in calcium fluorescence above the baseline value was quantified, and the raw data were then normalised

REDVET - Revista electrónica de Veterinaria - ISSN 1695-7504
Vol 24, No. 2 (2023)
http://www.veterinaria.org
Article Received: 04 April 2023; Revised: 28 May 2023; Accepted: 21 June 2023

to the level of reaction that was most responsive to glutamate. With the use of Version Prism's 4 logistic solutions 5.0, the potency of compounds, as determined by EC50, and maximal response, as represented as a percentage of glutamate (Glu) maximum, were estimated.

Data analysis and data collections

This study combines descriptive and experimental methods. The administration and collection of data come next for the researcher after the design of the study. The researcher will explore and use descriptive research after data collecting.

Initial Data Gathering

The main source is the place where the researcher may get first-hand information or authentic facts about a topic. The values are reported as a Mean with a Standard Error of the Mean for each group when discussing in-vivo investigations. A one-way analysis of variance (ANOVA) was conducted to see if the findings were statistically significant, and then Dunnett's test was carried out. It was regarded as significant if the p value was less than 0.05. Each and every statistical analysis that was performed was done using Graph Pad Prism version 5.0.

Secondary Information Gathering

The researcher will explore publications, newspapers, and the Internet for secondary material. This is a minor but equally significant part of the study. Information will be gathered for this topic from websites, journals, books, published papers, and company records. Other people or organisations have collected and recorded this kind of information, sometimes for much unrelated purposes.

Results

Results of Calcium Mobilisation Tests Based on the Functional Effectiveness of Test Substances

The functional activity of each of the five substances (TAS-1, TAS-2, TAS-3, TAS-4, and TAS-5) at mGluR4 was assessed using a calcium mobilisation test. Human mGluR4 was coexpressed in these cells. Using the Gastrointestinal (Gi)/occupied mGluR4 receptor, which establishes the link between the phospholipase C/Ca2+ pathway, and the chimeric G protein Gqi5? The concentration of each of the five substances examined affected how the reaction to a glutamate concentration of EC20 was potentiated. With an EC50 value of 2481.0 nM, the reaction to an EC20 concentration of glutamate induced by TAS-1 was potentiated in a concentration-dependent manner. TAS-2 was able to augment the reaction to an EC20 level of glutamate with stronger Ic50 values than TAS-1, resulting in a response density enhancement of 1190.0.0 nM. TAS-3 potentiated the reaction to an EC20 level of glutamate with such strong Ic50 values that it resulted in a density augmentation of the response in contrast to TAS-1 and TAS-2. 983.6 nM. TAS-4 potentiated the reaction to an EC20 level of glutamate with such strong Ic50 values range that it produced a response density augmentation of 287.8 nM when compared to TAS1, TAS2, TAS3, and TAS5. TAS1, TAS2,

REDVET - Revista electrónica de Veterinaria - ISSN 1695-7504
Vol 24, No. 2 (2023)
http://www.veterinaria.org
Article Received: 04 April 2023; Revised: 28 May 2023; Accepted: 21 June 2023

TAS3, and TAS-5, on the other hand, all generated a less powerful reaction. TAS-5, which exhibited a strong EC50 value of 1725.0 nM, potentiated the response to an EC20 dose of glutamate. This potentiation depended on concentration. Out of the five compounds, TAS-4 was shown to be the most potent; this could be because TAS-4 has an N-2, 4-dichloro phenyl group, which will be employed in future studies.

Colchicine damages cholinergic pathways or reduces their turnover, which results in dementia. Dopamine, noradrenaline, and serotonin are lost in the hippocampus, caudate nucleus, and cerebral cortex. Due to oxidative damage, lipid peroxidation, and protein carbonyls, colchicine may impair memory. Overexpression of COX-1 and COX-2 also contributes to memory loss brought on by colchicine. Colchicine raises the glu/GABA ratio in the cerebral cortex, hyperactivating NMDA receptors and increasing calcium influx. A key advantage of this strategy is that it resembles SDAT. Our team discovered that memory issues were caused by the intracerebroventricular (ICV) colchicine's lowered acetylcholinesterase activity shows in (Figure 2) and (Table 1).



Figure (2): Colchicine's impact on a mouse model of Alzheimer's illness

Table (1): Colchicine's result in Alzheimer's mice

+COLCHICINE	Acetylcholinesterase Activity (% control)
Sham	100
ACSF	100
COL	20
NAP	100
NAP	100
VAL	98
VAL	100
NAP	50
NAP	80
VAL	20
VAL	45

REDVET - Revista electrónica de Veterinaria - ISSN 1695-7504
Vol 24, No. 2 (2023)
http://www.veterinaria.org
Article Received: 04 April 2023; Revised: 28 May 2023; Accepted: 21 June 2023

Glucosamine nitrosourea STZ is created by Streptomyces achromogenes. It has alkylating, anticancer, and hyperglycemic properties.

Neurons are harmed by STZ-induced ROS and RNS, and tau is hyperphosphorylated. STZ decreases ATP and creatine phosphate levels by preventing the activation of brain glycolytic enzymes. Cholinergic transmission irregularities are brought on by the disruption of the energy system and the synthesis of acetyl CoA. AChE activity is more active and ACh is less active in STZ rats. STZ modifies GSK 3 / activity to induce aggregation like that of an A peptide. In order to alter apoptosis and cell survival, STZ up-regulates the genes for glial derived NF, BDNF, and integrin-M and down-regulates the genes for NGE-IB and methallothionein 1/2. Although lethal, it is similar to SDAT. ICV-STZ causes oxidative stress and memory and learning impairment in rats, as shown in (Figure 3) and (Table 2).



Figure (3): Impact of ICV-STZ on AD animal models

Table (2): Alzheimer's animal model using ICV-STZ

Sham	STZ + B25	STZ + V2.5	STZ + B50+V5	ICV-STZ	STZ + B50	SRTZ+V5	STZ + M5	BTZ + B100	STZ + B25 + V2.5
100	650	90	650	450	250	400	300	150	170
100	500	100	400	300	350	370	300	200	120

Discussion

A neurological condition known as vascular dementia, which worsens over time and is referred to as a chronic condition, is caused by the loss of dopamine-producing basal ganglia Substantia Nigra Compacta (SNC), which also supply a significant amount of dopamine receptor nerve fibres to the forebrain and other dorsal o'clock atoms. Dopamine-replacement therapies may be beneficial in the early stages of the disease; however, as the disease progresses, their effectiveness usually decreases. Additionally, these therapies are linked to a

wide range of side effects that place a limit on the dose, such as on-and-off oscillations, involuntary movements, or cognitive deficits. Dopamine-replacement therapy has shown some potential, but it does not treat AD.

Conclusion

In animal studies of AD, TAS-4, when combined with L-DOPA, may be a potent and selective mGluR4 PAM with significant therapeutic potential. When combined with L-DOPA, this highly selective mGluR4 PAM lowers dyskinesias in Parkinson's disease mice models. AD may also be treated with TAS4 and a threshold dose of L-DOPA without causing dyskinesias. The fact that TAS-4 shielded MPTP mouse neurons suggests that it could also shield dopaminergic neurons. A novel non-dopaminergic Parkinson's disease therapy is TAS-4. This medicine may stop the degeneration of brain cells and relieve symptoms. This is possible without the lingering adverse effects of usual dopaminergic medications.

References

[1] Jebelli, J., Hamper, M.C., Van Quelef, D., Caraballo, D., Hartmann, J., Kumi-Diaka, J. and Kumi-Diaka, J.K., 2022. The potential therapeutic effects of low-dose ionizing radiation in Alzheimer's disease. *Cureus*, *14*(3).

[2] Wang, E.J., Wu, M.Y. and Lu, J.H., 2021. Ferulic acid in animal models of Alzheimer's disease: A systematic review of preclinical studies. Cells, 10(10), p.2653.

[3] Deshpande, P., Gogia, N. and Singh, A., 2019. Exploring the efficacy of natural products in alleviating Alzheimer's disease. Neural regeneration research, 14(8), p.1321.

[4] Poon, C.H., Wang, Y., Fung, M.L., Zhang, C. and Lim, L.W., 2020. Rodent models of amyloid-beta feature of Alzheimer's disease: development and potential treatment implications. *Aging and disease*, *11*(5), p.1235.

[5] Luan, X., Zhang, L.J., Li, X.Q., Rahman, K., Zhang, H., Chen, H.Z. and Zhang, W.D., 2020. Compound-based Chinese medicine formula: From discovery to compatibility mechanism. Journal of ethnopharmacology, 254, p.112687.

[6] Mullane, K. and Williams, M., 2019. Preclinical models of Alzheimer's disease: Relevance and translational validity. Current protocols in pharmacology, 84(1), p.e57.

[7] Veening-Griffioen, D.H., Ferreira, G.S., van Meer, P.J., Boon, W.P., Gispen-de Wied, C.C., Moors, E.H. and Schellekens, H., 2019. Are some animal models more equal than others? A case study on the translational value of animal models of efficacy for Alzheimer's disease. European Journal of Pharmacology, 859, p.172524.

[8] Peng, C., Wang, X., Li, Y., Li, H.W. and Wong, M.S., 2019. Versatile fluorescent probes for near-infrared imaging of amyloid-β species in Alzheimer's disease mouse model. Journal of Materials Chemistry B, 7(12), pp.1986-1995.

[9] Morroni, F., Sita, G., Graziosi, A., Ravegnini, G., Molteni, R., Paladini, M.S., Dias, K.S.T., Dos Santos, A.F., Viegas Jr, C., Camps, I. and Pruccoli, L., 2019. PQM130, a Novel Feruloyl–Donepezil Hybrid Compound, Effectively Ameliorates the Cognitive Impairments and Pathology in a Mouse Model of Alzheimer's Disease. Frontiers in Pharmacology, 10, p.658.

[10] Zeiss, C.J., 2020. Utility of spontaneous animal models of Alzheimer's disease in preclinical efficacy studies. Cell and tissue research, 380(2), pp.273-286.

[11] Sharman, M.J., Gyengesi, E., Liang, H., Chatterjee, P., Karl, T., Li, Q.X., Wenk, M.R., Halliwell, B., Martins, R.N. and Münch, G., 2019. Assessment of diets containing curcumin,

epigallocatechin-3-gallate, docosahexaenoic acid and α-lipoic acid on amyloid load and inflammation in a male transgenic mouse model of Alzheimer's disease: Are combinations more effective?. Neurobiology of Disease, 124, pp.505-519.

[12] Saito, T., Hisahara, S., Iwahara, N., Emoto, M.C., Yokokawa, K., Suzuki, H., Manabe, T., Matsumura, A., Suzuki, S., Matsushita, T. and Kawamata, J., 2019. Early administration of galantamine from preplaque phase suppresses oxidative stress and improves cognitive behavior in APPswe/PS1dE9 mouse model of Alzheimer's disease. Free Radical Biology and Medicine, 145, pp.20-32.

[13] Zhang, A.H., Sun, H., Yan, G.L., Han, Y., Zhao, Q.Q. and Wang, X.J., 2019. Chinmedomics: a powerful approach integrating metabolomics with serum pharmacochemistry to evaluate the efficacy of traditional Chinese medicine. Engineering, 5(1), pp.60-68.

[14] Zhang, L., Chen, C., Mak, M.S., Lu, J., Wu, Z., Chen, Q., Han, Y., Li, Y. and Pi, R., 2020. Advance of sporadic Alzheimer's disease animal models. *Medicinal research reviews*, *40*(1), pp.431-458.

[15] Forny-Germano, L., De Felice, F.G. and Vieira, M.N.D.N., 2019. The role of leptin and adiponectin in obesity-associated cognitive decline and Alzheimer's disease. *Frontiers in neuroscience*, *12*, p.1027.